LBL-061 / Leads Biolabs - LARVOL DELTA

LBL-061: A novel EGFR×PD-L1 targeted drug conjugate for the treatment of multiple solid tumors (AACR 2026) - "Our findings indicate that LBL-061, a novel bispecific EGFR×PD-L1-targeting ADC synergizes antitumor effects by combining direct cytotoxicity and immune activation. It showed a favorable PK profile and a good safety profile in cynomolgus monkeys. Taken together, these preclinical data strongly suggest that LBL-061 is a promising candidate worthy of further clinical investigation."

IO biomarker • Head and Neck Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • EGFR • PD-L1

LBL-061 Poster Presentation (HKEXnews) - "...Abstracts accepted for presentation at the 2026 AACR Annual Meeting....Preclinical studies show that LBL-061 exhibits potent binding and cytotoxicity against a range of tumor cell lines, along with strong PD-1/PD-L1 blocking activity. In a PBMC-tumor cell co-culture system, it can induce immunogenic cell death (ICD) in tumor cells and mediate a potent bystander effect on EGFR-negative tumor cells. In vivo studies demonstrate excellent tumor growth inhibition in both syngeneic and xenograft mouse models."

Preclinical • Solid Tumor